Cornerstone Management’s GSK GSK Stock Holding History

Cornerstone Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22	Closed	-$783	–	130
2023 Q1	$783	Hold	22	–	–	﹤0.01%	231
2022 Q4	$774	Hold	22	–	–	﹤0.01%	225
2022 Q3	$648	Hold	22	–	–	﹤0.01%	234
2022 Q2	$1.22K	Hold	22	–	–	﹤0.01%	231
2022 Q1	$1.22K	Hold	22	–	–	﹤0.01%	232
2021 Q4	$1.24K	Buy	+22	New	+$1.14K	﹤0.01%	209

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cornerstone Management's GSK Position: Q2 2023 in Review

Cornerstone Management sold out of GSK (GSK) in Q2 2023, closing a stake of 22 shares — an estimated $783 sold.

Cornerstone Management first reported a position in GSK in Q4 2021 and held it in 6 quarters. The position peaked at $1.24K in Q4 2021. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

Cornerstone Management reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
Cornerstone Management sold 22 GSK shares in Q2 2023, an estimated $783.
Cornerstone Management first reported a position in GSK in Q4 2021 and held it in 6 quarters.
Cornerstone Management's GSK position peaked at $1.24K in Q4 2021.
827 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Cornerstone Management's 13F filing for Q2 2023, filed 10 Aug 2023.